Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$52.36
0.000.00%
Pre-Market: 4:00 PM EDT
Comments
Loading...
Tarsus Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:TARS | Benzinga
Tarsus Pharmaceuticals Inc has a consensus price target of $60.86 based on the ratings of 7 analysts. The high is $78 issued by Guggenheim on February 26, 2025. The low is $41 issued by Goldman Sachs on November 15, 2024. The 3 most-recent analyst ratings were released by Jefferies, Guggenheim, and HC Wainwright & Co. on March 6, 2025, February 26, 2025, and February 26, 2025, respectively. With an average price target of $69.67 between Jefferies, Guggenheim, and HC Wainwright & Co., there's an implied 33.05% upside for Tarsus Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
Guggenheim
HC Wainwright & Co.
Barclays
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Tarsus Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/06/2025 | Buy Now | 10.77% | Jefferies | Anthony Petrone65% | $54 → $58 | Maintains | Buy | Get Alert |
| 02/26/2025 | Buy Now | 48.97% | Guggenheim | Eddie Hickman63% | $75 → $78 | Maintains | Buy | Get Alert |
| 02/26/2025 | Buy Now | 39.42% | HC Wainwright & Co. | Oren Livnat61% | $73 → $73 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2025 | Buy Now | 14.59% | Barclays | Balaji Prasad53% | $62 → $60 | Maintains | Overweight | Get Alert |
| 02/24/2025 | Buy Now | — | Guggenheim | Eddie Hickman63% | — | Reiterates | Buy → Buy | Get Alert |
| 02/10/2025 | Buy Now | — | Guggenheim | Eddie Hickman63% | — | Reiterates | Buy → Buy | Get Alert |
| 01/27/2025 | Buy Now | 18.41% | Barclays | Balaji Prasad53% | $60 → $62 | Maintains | Overweight | Get Alert |
| 01/22/2025 | Buy Now | 37.51% | Oppenheimer | Francois Brisebois44% | $65 → $72 | Maintains | Outperform | Get Alert |
| 11/15/2024 | Buy Now | -21.7% | Goldman Sachs | Andrea Tan41% | $36 → $41 | Maintains | Neutral | Get Alert |
| 11/14/2024 | Buy Now | 24.14% | Oppenheimer | Francois Brisebois44% | $63 → $65 | Maintains | Outperform | Get Alert |
| 08/09/2024 | Buy Now | 20.32% | Oppenheimer | Francois Brisebois44% | $61 → $63 | Reiterates | Outperform → Outperform | Get Alert |
| 05/13/2024 | Buy Now | 16.5% | HC Wainwright & Co. | Oren Livnat61% | $57 → $61 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 14.59% | Barclays | Balaji Prasad53% | $50 → $60 | Maintains | Overweight | Get Alert |
| 05/09/2024 | Buy Now | 16.5% | Oppenheimer | Francois Brisebois44% | $59 → $61 | Maintains | Outperform | Get Alert |
| 03/06/2024 | Buy Now | -15.97% | Jefferies | Anthony Petrone65% | $30 → $44 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | -42.7% | Goldman Sachs | Andrea Tan41% | $19 → $30 | Maintains | Neutral | Get Alert |
| 02/28/2024 | Buy Now | 8.86% | HC Wainwright & Co. | Oren Livnat61% | $50 → $57 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | -4.51% | Barclays | Balaji Prasad53% | $40 → $50 | Maintains | Overweight | Get Alert |
| 02/28/2024 | Buy Now | 12.68% | Oppenheimer | Francois Brisebois44% | $55 → $59 | Reiterates | Outperform → Outperform | Get Alert |
| 11/20/2023 | Buy Now | -63.71% | Goldman Sachs | Andrea Tan41% | → $19 | Initiates | → Neutral | Get Alert |
| 11/10/2023 | Buy Now | -4.51% | HC Wainwright & Co. | Oren Livnat61% | $42 → $50 | Maintains | Buy | Get Alert |
| 09/11/2023 | Buy Now | -6.42% | Guggenheim | Eddie Hickman63% | $46 → $49 | Maintains | Buy | Get Alert |
| 08/14/2023 | Buy Now | -12.15% | Guggenheim | Eddie Hickman63% | → $46 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | -19.79% | HC Wainwright & Co. | Oren Livnat61% | $50 → $42 | Maintains | Buy | Get Alert |
| 07/26/2023 | Buy Now | -4.51% | HC Wainwright & Co. | Oren Livnat61% | $44 → $50 | Maintains | Buy | Get Alert |
| 07/18/2023 | Buy Now | -15.97% | William Blair | — | → $44 | Initiates | → Outperform | Get Alert |
| 06/26/2023 | Buy Now | -15.97% | HC Wainwright & Co. | Oren Livnat61% | $40 → $44 | Maintains | Buy | Get Alert |
| 06/16/2023 | Buy Now | -19.79% | Guggenheim | Eddie Hickman63% | $40 → $42 | Maintains | Buy | Get Alert |
| 05/18/2023 | Buy Now | — | Guggenheim | Eddie Hickman63% | — | Initiates | → Buy | Get Alert |
| 05/08/2023 | Buy Now | -17.88% | Oppenheimer | Francois Brisebois44% | → $43 | Reiterates | → Outperform | Get Alert |
| 03/15/2023 | Buy Now | -23.61% | HC Wainwright & Co. | Oren Livnat61% | → $40 | Reiterates | → Buy | Get Alert |
| 08/01/2022 | Buy Now | -23.61% | Barclays | Balaji Prasad53% | → $40 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Tarsus Pharmaceuticals (TARS) stock?
The latest price target for Tarsus Pharmaceuticals (NASDAQ:TARS) was reported by Jefferies on March 6, 2025. The analyst firm set a price target for $58.00 expecting TARS to rise to within 12 months (a possible 10.77% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Tarsus Pharmaceuticals (TARS)?
The latest analyst rating for Tarsus Pharmaceuticals (NASDAQ:TARS) was provided by Jefferies, and Tarsus Pharmaceuticals maintained their buy rating.
When was the last upgrade for Tarsus Pharmaceuticals (TARS)?
There is no last upgrade for Tarsus Pharmaceuticals
When was the last downgrade for Tarsus Pharmaceuticals (TARS)?
There is no last downgrade for Tarsus Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Tarsus Pharmaceuticals (TARS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tarsus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tarsus Pharmaceuticals was filed on March 6, 2025 so you should expect the next rating to be made available sometime around March 6, 2026.
Is the Analyst Rating Tarsus Pharmaceuticals (TARS) correct?
While ratings are subjective and will change, the latest Tarsus Pharmaceuticals (TARS) rating was a maintained with a price target of $54.00 to $58.00. The current price Tarsus Pharmaceuticals (TARS) is trading at is $52.36, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.